Contribute Try STAT+ Today

WASHINGTON — The House of Representatives is fast-tracking a vote on a key priority for the pharmaceutical industry, but the measure faces a tougher path in the Senate, where concerns over drug prices and broader political animosity over repeal efforts could drag out the process.

The package would update the contracts that govern the relationship between drug and device makers and the Food and Drug Administration and that spell out how the industry would fund the agency’s oversight and approval processes. The legislation is considered critical for the functioning of the FDA, and agency leaders have warned they will lay off employees if Congress does not approve the legislation before the end of the fiscal year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.